- All the pediatric subjects (aged 3-15 years) whom an investigator prescribes the
first gabapentin (tablets, syrup, and switch to syrup from tablet) should be
registered consecutively until the number of subjects reaches target number in order
to extract patients enrolled into the investigation at random.
- Patients who have been enrolled in the drug use investigation of Gabapen tablets in
adults (protocol No. A9451163).
- Patients who receive Gabapen tablets or syrup before, except for switched from
tablets to syrup.